1. Home
  2. NTRA vs SW Comparison

NTRA vs SW Comparison

Compare NTRA & SW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTRA
  • SW
  • Stock Information
  • Founded
  • NTRA 2003
  • SW 1934
  • Country
  • NTRA United States
  • SW Ireland
  • Employees
  • NTRA N/A
  • SW N/A
  • Industry
  • NTRA Medical Specialities
  • SW
  • Sector
  • NTRA Health Care
  • SW
  • Exchange
  • NTRA Nasdaq
  • SW Nasdaq
  • Market Cap
  • NTRA 27.0B
  • SW 21.6B
  • IPO Year
  • NTRA 2015
  • SW N/A
  • Fundamental
  • Price
  • NTRA $199.57
  • SW $35.71
  • Analyst Decision
  • NTRA Strong Buy
  • SW Strong Buy
  • Analyst Count
  • NTRA 18
  • SW 10
  • Target Price
  • NTRA $206.17
  • SW $56.00
  • AVG Volume (30 Days)
  • NTRA 1.3M
  • SW 5.2M
  • Earning Date
  • NTRA 11-06-2025
  • SW 10-29-2025
  • Dividend Yield
  • NTRA N/A
  • SW 4.81%
  • EPS Growth
  • NTRA N/A
  • SW 109.39
  • EPS
  • NTRA N/A
  • SW 1.42
  • Revenue
  • NTRA $2,116,676,000.00
  • SW $31,138,000,000.00
  • Revenue This Year
  • NTRA $25.70
  • SW $52.91
  • Revenue Next Year
  • NTRA $15.42
  • SW $3.09
  • P/E Ratio
  • NTRA N/A
  • SW $25.16
  • Revenue Growth
  • NTRA 38.17
  • SW 89.50
  • 52 Week Low
  • NTRA $125.38
  • SW $35.00
  • 52 Week High
  • NTRA $203.23
  • SW $56.99
  • Technical
  • Relative Strength Index (RSI)
  • NTRA 69.72
  • SW 28.03
  • Support Level
  • NTRA $193.29
  • SW $35.21
  • Resistance Level
  • NTRA $203.23
  • SW $37.10
  • Average True Range (ATR)
  • NTRA 7.37
  • SW 1.20
  • MACD
  • NTRA 0.25
  • SW -0.52
  • Stochastic Oscillator
  • NTRA 80.29
  • SW 7.99

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About SW Smurfit WestRock plc Ordinary Shares

Smurfit WestRock manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. After the merger of Smurfit Kappa and WestRock in summer 2024, Smurfit WestRock became the largest producer of containerboard in the world, with substantial operations in North America, South America, and Europe.

Share on Social Networks: